|By PR Newswire||
|February 17, 2014 07:37 AM EST||
LONDON, Feb. 17, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
Emerging Technology and Major Partnerships in Influenza Vaccines
Influenza is a burgeoning problem across the entire globe, there is an increased need for new therapeutic methods. A whole host of technology platforms are being utilized to create non egg based vaccines. The world has not seen an influenza pandemic, and in terms of historical occurrences, we are several years overdue of one. There is a critical need for a universal vaccine, that has the potential to prevent multiple strains of influenza, so that yearly vaccinations can be eliminated and healthcare costs can be reduced. The main focus of the research service features the influenza vaccine market and the types of emerging technologies as well as developing partnerships over 2010-2013.
1. The Influenza therapeutics industry can be split into two main segments the antiviral industry and the influenza vaccines industry. There is a lot of funding for these industries to ensure protection for the global population against seasonal and pandemic influenza. Companies are striving to cover everyone, including the high-risk groups, such as children below the age of 2, adults above the age of 65, and people with preexisting medical conditions.
2. The influenza vaccine industry is witnessing a shift from the conventional egg-based vaccine development methods to more novel approaches. Some of them being DNA-based, recombinant subunit-based and even microbial vector-based approaches. These approaches are proving to be more cost effective and seem to have a higher rate of mass production, which is crucial if an influenza pandemic surfaces.
3. Efforts are being directed toward covering a boarder spectrum of viral strains than those presently being covered by seasonal influenza vaccines. The FDA has approved quadrivalent vaccines for distribution during the 2013-2014 seasonal influenza which covers Xstrains. There has been an increase in collaborations for the development of these 'universal vaccines' across the globe.
4. Developing new modes of administration of influenza vaccines is also an avenue that is being heavily explored by large and small biotechnology companies. They aim to eliminate the need for a needle and make it less invasive; this seems to be the primary focus of most research efforts. Some of the more nascent forms of administrating vaccines are oral vaccines and vaccine patches.
5. Looking more into R&D in a geographic perspective, there is a lot of funding going into influenza therapeutics in the US. In Europe, there is greater focus of R&D on new antiviral drug therapies and less focus on the vaccine industry. There is increasing focus on R&D in Asia Pacific and various new developments have taken place on the vaccine front, especially in countries, such as Singapore and Australia.
Influenza is a form of viral infection that can spread rapidly between people. It affects almost every age group and tends to impact the economy due to a significant decrease in productivity when employed professionals take sick leave. Seasonal epidemics usually affect the northern hemisphere (temperate regions) during the winter months. According to the Centers for Disease Control (CDC), worldwide influenza affects about Xmillion people annually and causes anywhere between X to Xdeaths. Children below the age of two, senior citizens ( over 65 years) and people who already have medical aliments, fall under the high-risk group. Seasonal influenza can be prevented by annual vaccinations against the prevalent strains for that season.
Influenza strains tend to rapidly mutate, aiding them in gaining resistance against the influenza vaccinations and antiviral drugs. Scientists in university laboratories and pharmaceuticals are trying to develop universal vaccines, that will provide patients boarder coverage against multiple influenza strains.
Looking at the larger picture, the influenza therapeutics industry has been experiencing many crucial changes. There are quite a few technical and business challenges that require immediate attention. The healthcare industry in general is moving toward preventative treatment options. Vaccine improvements will benefit all age groups as well as people with pre-existing conditions. The target demographics for these vaccines will increase , subsequently reducing epidemics across the globe.
Referencing sources on previous pandemics that have occurred, an influenza pandemic is currently overdue, which is an important point to note, as challenges with regards to pandemic influenza vaccinations need to be addressed immediately, to stay abreast with the situation of a potential pandemic.
The research service covers the following:
• Captures technologies used for influenza therapeutics and highlights innovations in the influenza vaccines and antiviral industry Orientation of research for existing and emerging diseases.
• Outlines the research portfolio, key trends and addresses the key technical challenges and key market challenges, and key performance
• Identifies opportunities in the field of targeted drug delivery for emerging and existing applications
• Provides strategic insights by highlighting the key performance indicators in the influenza therapeutics industry
• Highlights partnerships/collaborations at a global level for enhancing the development of influenza vaccines and entering into the market
• Provides strategic recommendations and conclusions, for companies working on influenza therapeutics to identify areas of growth
• Analytical Hierarchy Process (AHP) that analyzes the current research portfolio adopted by most companies for existing and emerging diseases.
Influenza Therapeutics Snapshot
• The influenza therapeutics market is valued at more than US $6 billion. (Frost & Sullivan Research Services)
• The Influenza vaccines segment is the largest and is expected to be $X billion
• The market is dominated by prophylactic vaccines for seasonal influenza treatments.
• Trivalent intramuscular vaccines form the largest market share under prophylactic vaccines.
• It is projected that quadrivalent vaccines will start dominating the market over the next five to seven years.
Influenza Therapeutics Market
Influenza Vaccines: X%
Antiviral Drugs: X%
Presently influenza vaccines are based of two forms. One is the inactivated form that is usually delivered as an injection and the live attenuated form, that is delivered intranasally. The inactivated form can be further spilt into X different segments--the whole virus vaccine, split virus vaccine, and the subunit vaccine. These conventional methods predominantly use an egg-based production methodology. The present technology trend is moving toward reducing the egg-based production approach and delving deeper into cell-based production approaches.
The cell-based approaches are still under development and do not have any standardized protocols. There is also a lot of government, and private funded research taking place in small biotechnology companies and universities that are focusing on innovating novel technology platforms to produce and manufacture influenza vaccines. The conventional methods of production are not cost effective and take a long time to produce, approximately 6 to 9 months is needed for a flu vaccine to become available to the end user population. These novel and nascent technologies are aimed at solving challenges involving high cost of production and reduce the time required for the vaccine to become available to the end users.
• Influenza, commonly known as 'flu' is a respiratory infection caused by RNA viruses in the Orthomxyoviridae family.
• It is divided into three subtypes A, B and C, based on antigenic and genetic differences in their hemagglutinin (HA) and neuraminidase (NA) glycoproteins present on the surface of the virus.
• Seasonal human influenza is caused by types A and B, whereas type C occurs rarely as a mild disease in children
• Currently, the H1N1, H3N2, H5N1 strains of influenza are prevalent in humans and extensive research is being undertaken for developing therapeutics against these strains.
Influenza Subtype A
• Most of the common influenza epidemics affecting the human population are predominantly caused by this particular subtype of influenza. They are constantly mutating due to antigenic shifts. Two very important proteins that are present on the viral surface are hemagglutinin (HA) and neuraminidase (NA). At present, there are around X different subtypes of HA and 9 forms of NA. This form of influenza tends to undergo both the antigenic drift as well as the antigenic shift.
Influenza Subtype B
• This genus of virus, tends to mutate at a much slower rate than the influenza virus A. But unfortunately, most vaccinations do not give lasting immunity for this strain due to the manner in which they mutate.
• Mutations also happen due to antigenic shifts similar to Influenza virus A . This genus is found only in humans unlike Influenza virus A.
Influenza Subtype C
• This is a lot rarer compare to influenza virus A & B, but it has also been known to cause some epidemics which can be severe in intensity.
Table of Contents
Executive Summary 4
•Key Findings 5
•Research Scope 6
•Segmentation of Influenza Therapeutics 7
•Influenza Therapeutics Snapshot 8
Technology Snapshot 9
•Influenza Overview 10
Strategic Assessment of Industry Environment 11
•R& D Portfolio Analysis - Vaccines 12
• By Technology 13
• By Mode of Administration 19
•R& D Portfolio Analysis - Antivirals 20
•By Technology 21
•Industry Value Chain 22
•Stakeholder Overview 23
•Industry Participants -- By Technology 25
•Research Orientation 28
•Geographic Overview 30
Partnership & Alliances 32
R&D Budgetary Analysis 40
Environmental Analysis 48
•Technology Challenges 50
•Market Challenges 53
Strategic Evaluation of Research and Development Portfolio 57
•AHP – Analytical Hierarchy Process Based Tree 58
Contacts, Patents & DSD Tables 65
The Frost & Sullivan Story 81
Read the full report:
Developments and Trends in Influenza Therapeutics (Technical Insights)
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
Aug. 4, 2015 06:45 PM EDT Reads: 239
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...
Aug. 4, 2015 06:45 PM EDT Reads: 220
SYS-CON Events announced today that the "Second Containers & Microservices Expo" will take place November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Containers and microservices have become topics of intense interest throughout the cloud developer and enterprise IT communities.
Aug. 4, 2015 05:30 PM EDT
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his session at 17th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Partnerships at Com...
Aug. 4, 2015 05:00 PM EDT Reads: 110
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
Aug. 4, 2015 03:00 PM EDT Reads: 573
Scrum Alliance has announced the release of its 2015 State of Scrum Report. Almost 5,000 individuals and companies worldwide participated in this year's survey. Most organizations in the market today are still leading and managing under an Industrial Age model. Not only is the speed of change growing exponentially, Agile and Scrum frameworks are showing companies how to draw on the full talents and capabilities of those doing the work in order to continue innovating for success.
Aug. 4, 2015 02:45 PM EDT
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
Aug. 4, 2015 02:00 PM EDT Reads: 391
Between the compelling mockups and specs produced by your analysts and designers, and the resulting application built by your developers, there is a gulf where projects fail, costs spiral out of control, and applications fall short of requirements. In his session at @DevOpsSummit, Charles Kendrick, CTO and Chief Architect at Isomorphic Software, presented a new approach where business and development users collaborate – each using tools appropriate to their goals and expertise – to build mocku...
Aug. 4, 2015 01:30 PM EDT
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
Aug. 4, 2015 01:00 PM EDT Reads: 295
SYS-CON Events announced today that VividCortex, the monitoring solution for the modern data system, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The database is the heart of most applications, but it’s also the part that’s hardest to scale, monitor, and optimize even as it’s growing 50% year over year. VividCortex is the first unified suite of database monitoring tools specifically desi...
Aug. 4, 2015 12:00 PM EDT Reads: 116
Graylog, Inc., has added the capability to collect, centralize and analyze application container logs from within Docker. The Graylog logging driver for Docker addresses the challenges of extracting intelligence from within Docker containers, where most workloads are dynamic and log data is not persisted or stored. Using Graylog, DevOps and IT Ops teams can pinpoint the root cause of problems to deliver new applications faster and minimize downtime.
Aug. 4, 2015 11:45 AM EDT
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Aug. 4, 2015 11:30 AM EDT Reads: 120
Learn how you can use the CoSN SEND II Decision Tree for Education Technology to make sure that your K–12 technology initiatives create a more engaging learning experience that empowers students, teachers, and administrators alike.
Aug. 4, 2015 09:30 AM EDT Reads: 120
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
Aug. 4, 2015 08:45 AM EDT Reads: 265
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
Aug. 4, 2015 07:00 AM EDT Reads: 227